Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This Item 5.07 disclosure presents the complete voting results from AerSale's Annual Meeting of Stockholders held June 11, 2026, including election of seven directors, advisory vote on executive compensation, redomestication from Delaware to Texas, and auditor ratification. All four proposals passed, with detailed vote tallies for each item. This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and key corporate governance matters.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-06-17
EX-99.1
This is a press release announcing Waterdrop Inc.'s unaudited financial results for the first quarter of 2026 (three months ended March 31, 2026). The document discloses net operating revenue of RMB1,242.2 million (up 64.8% YoY), operating profit of RMB80.0 million, and net profit attributable to ordinary shareholders of RMB98.4 million, along with detailed segment results, balance sheet, and cash flow information. This is a discrete earnings announcement, not a periodic financial report filing itself, and constitutes a material event affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a clear disclosure of shareholder vote results from Stellus Capital's Annual Meeting of Stockholders held on June 16, 2026. The filing reports the voting outcomes for two proposals: (1) election of director Bruce R. Bilger with 13,650,012 votes for and 2,122,882 withheld, and (2) approval of a new investment advisory agreement with Stellus Capital Management, LLC with 14,244,374 votes for, 721,794 against, and 806,722 abstentions. This is a textbook Item 5.07 disclosure of shareholder meeting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on June 16, 2026. The filing reports that shareholders voted to approve a new investment advisory agreement between Stellus Private Credit BDC and Stellus Private BDC Advisor, LLC, with 10,314,546 votes in favor and zero votes against or abstaining. This is a material governance event requiring Item 5.07 disclosure under SEC rules.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-06-17
The 6-K discloses settlement of putative class action lawsuits filed against the Company and certain directors in federal and state courts. The Federal Court approved a $7 million settlement agreement on June 1, 2026, resolving the Eastern District of New York action (Case No. 1:22-cv-02604), and a separate state court action was voluntarily dismissed. The disclosure explicitly states "all of the putative class actions filed against the Company in federal and state courts in the U.S. have been resolved," indicating material litigation settlement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-17
Item 5.02
The filing discloses the appointment of Nick Jones as Chief Information Officer and Chief Operating Officer effective June 15, 2026, with detailed employment terms including $300,000 annual base salary, performance bonuses, and a $50,000 sign-on RSU grant. While the section also mentions Richard Alder's departure as COO, the principal disclosed action centers on Jones's appointment to a senior dual executive role with a three-year employment agreement, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
Verastem announced positive updated results from the RAMP 205 Phase 1b/2a clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer, with an 86% overall survival rate at 6 months, 68% progression-free survival rate, and 52% objective response rate. The company also announced initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-17
Item 5.02
The filing discloses the appointment of Richard H. Zay to Chief Operating Officer, effective July 1, 2026, a material executive promotion. While the disclosure also mentions compensatory arrangements ($400,000 in equity awards), the principal action is the appointment to a C-suite position. This is material to investors as it reflects a significant change in executive leadership and succession planning.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-06-17
EX-99.1
Franco-Nevada discloses a material legal dispute arising from a Burkina Faso court decision purporting to nullify a stream agreement related to the Karma Mine. The company states it believes the judgment is invalid and is pursuing legal remedies in Ontario and elsewhere against Riverstone Karma SA and affiliates to protect its legal rights. This is a material litigation/dispute disclosure that would affect a reasonable investor's assessment of the company's cash-flow-producing assets and portfolio value.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-17
Item 1.01
This disclosure describes the entry into multiple material definitive agreements in connection with the issuance and sale of asset-backed securities (Notes) on June 17, 2026. The core transaction involves a Receivables Purchase Agreement whereby HCA transferred retail installment sale contracts to HABS, followed by a Sale and Servicing Agreement transferring those receivables to a trust that issued the Notes. This constitutes a material securitization transaction—a form of asset disposition and financing activity that would materially affect the registrant's financial position and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of ATN International's Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting tallies for three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
Enterprise Financial Services Corp completed a $175 million issuance of subordinated notes on June 17, 2026, pursuant to a registered offering under Form S-3, creating material direct financial obligations and expanding the company's capital structure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-17
The filing discloses adoption of new forms of equity award agreements (RSU, stock option, and common stock agreements) under the 2021 Incentive Award Plan and grants of time-based RSUs to three named executive officers (Dave Lillis, Jeff Mayfield, and Ryan Salmons) totaling approximately $319,636 in aggregate grant-date fair value. Item 5.02(e) explicitly identifies these as "material compensatory arrangements," and the disclosure details vesting structures, fair values, and vesting commencement dates for each executive.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-17
Item 7.01
The filing discloses a proposed business combination between Nano Dimension Ltd. and Infinite Epigenetics, Inc., with a press release issued on June 16, 2026 providing additional information about the transaction. The disclosure references an anticipated Definitive Agreement, Form S-4 registration statement, and proxy statement/prospectus, all hallmarks of a material M&A transaction requiring shareholder approval. This is a material event that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This Item 5.07 filing discloses the results of Regeneron's 2026 Annual Meeting of Shareholders held on June 12, 2026, including voting outcomes for three proposals: election of Class II directors (five nominees), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
Madrigal Pharmaceuticals held its Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on five matters: re-election of three Class I directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Stock Plan, and approval of the 2026 Employee Stock Purchase Plan. The filing discloses complete voting tallies (For, Against, Abstentions, Broker Non-Votes) for each matter.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-17
Item 5.02
The Board adopted a Nonqualified Deferred Compensation Plan for named executive officers and directors, and entered into a consulting agreement with Dr. Rebecca Taub (Class II director) providing $100,000 annually plus director compensation. These compensatory arrangements were approved by stockholders as part of the Annual Meeting voting on the 2026 Stock Plan and 2026 Employee Stock Purchase Plan.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 1.01
This disclosure reports a seventh amendment to a business combination agreement (BCA) between Israel Acquisitions Corp and Gadfin Ltd., originally entered into on January 26, 2025 and amended multiple times through June 15, 2026. The amendment extends the termination date under Section 7.1(d) to June 20, 2026. This constitutes material M&A activity under Item 1.01, as it involves an ongoing material acquisition/business combination and modification of its key terms.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-17
Item 2.01
Avalanche Treasury Corp completed a business combination with MLAC on June 11, 2026, following shareholder approval on June 4, 2026. The transaction involved entry into material definitive agreements (registration rights, indemnification, and lock-up agreements), significant shareholder redemptions of $243.2 million, and resulted in a change of control with a post-closing capitalization of 37.9 million Class A shares and 5.8 million Class B shares outstanding.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-17
Item 5.02
Three executive officers were appointed effective on the business combination closing date: Gerald Bartholomew Smith as CEO/President, Laine Mihalchick Moljo as COO/Secretary, and Sean Ostrower as CFO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-17
Item 3.02
Pubco completed an unregistered private placement sale of equity securities to the Foundation under Section 4(a)(2) of the Securities Act in connection with the business combination.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 3.03
The registrant adopted a First Amended and Restated Certificate of Incorporation and Bylaws in connection with the business combination closing, materially modifying the rights of Class A stockholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This Item 5.07 disclosure reports the results of Aprea Therapeutics' 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on six proposals: election of three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratification of EisnerAmper LLP as auditor, approval of a reverse stock split authorization (1-for-3 to 1-for-8 ratio), advisory votes on executive compensation and compensation vote frequency, and adjournment authority. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a significant capital structure change that would affect all shareholders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-17
Item 5.02
The filing discloses the appointment of Tyler Krutzig as Senior Vice President and Chief Accounting Officer effective September 1, 2026, following the announced retirement of Randolph A. Wacker. While both a departure and appointment occur, the principal disclosed action centers on the appointment of Krutzig to a key executive role (Chief Accounting Officer), making exec_appointment the most salient classification. The appointment is material as it involves a named executive officer in a critical financial reporting position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a clear disclosure of shareholder vote results from Vuzix's June 16, 2026 annual meeting of stockholders. The filing reports voting outcomes on three matters: (i) election of five directors (Paul Travers, Grant Russell, Timothy Harned, Paula Whitten-Doolin, and Alasdair MacKinnon), (ii) ratification of Withum Smith+Brown, PC as independent auditor, and (iii) advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstained, and broker non-votes) are presented in tabular form, which is the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-17
Item 5.02
John E. Gallagher III, Senior Vice President and Chief Financial Officer, resigned effective July 14, 2026. Faiz Mohammed was appointed as Interim CFO to manage the transition.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-06-17
EX-99.1
BGM Group Ltd. has scheduled an Extraordinary General Meeting for July 9, 2026, to vote on five shareholder proposals including share capital reduction, amendment to memorandum and articles of association, potential share consolidation, post-consolidation capital increase, and adoption of new M&A provisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 1.01
Medalist Diversified entered into a definitive agreement to sell Brookfield Center, a commercial real property, for $10.25 million. This disposition of a material asset is substantial relative to the registrant's size and will materially affect its asset base and financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
At the Annual Meeting of stockholders, four proposals were voted on and all passed with substantial majorities: election of two Class III directors (Kavanaugh and Farmer), advisory approval of named executive officer compensation, ratification of Cherry Bekaert LLP as independent auditor, and approval of a charter amendment to protect net operating loss and net capital loss carryforwards through transfer restrictions.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-06-17
The 6-K discloses payment of the third installment of a cash dividend authorized by the General Shareholders' Meeting on April 8, 2026, in the amount of AR $49,033,753,984.66 (AR $76.6882980676 per share), to be made available as of July 7, 2026. This is a material distribution to shareholders that would affect investor assessment of capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Liquidia's June 16, 2026 annual meeting. The filing reports voting outcomes on three proposals: election of three Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and non-binding advisory approval of NEO compensation. All three proposals passed with substantial majorities, and the detailed vote tallies (For/Against/Abstain/Broker Non-Votes) are provided for each matter.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-06-17
Item 2.02
The company issued a press release on June 17, 2026 reaffirming full-year 2026 revenue growth guidance previously provided in the first quarter earnings release, disclosed under Item 2.02 with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-17
Item 5.02
Jayant Chauhan was appointed as Executive Vice President and Chief Financial Officer, effective July 6, 2026, replacing interim CFO Marissa Espineli. The appointment includes a base salary of $460,000, bonus targets, an RSU grant of $1.3 million, and severance provisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-17
Item 1.01
Plains All American Pipeline entered into a new $2.7 billion senior unsecured revolving credit facility on June 12, 2026, which replaces two prior credit agreements and expands to $4.0 billion. This consolidation of two existing facilities into a single, larger credit arrangement represents a material refinancing that enhances the Partnership's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-06-17
The filing discloses that QVC Group, Inc. and certain affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas on April 16, 2026. While this 8-K is technically filed under Item 7.01 (Regulation FD Disclosure) to furnish monthly operating reports required by the Bankruptcy Code, the core material event is the Chapter 11 bankruptcy filing itself, which was previously disclosed on April 16, 2026. This is a terminal signal event of the highest materiality.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-17
Item 1.02
Plains GP Holdings terminated two material credit facilities (the Existing Revolving Credit Agreement and the Hedged Inventory Facility) and closed a new Revolving Credit Agreement, representing a routine refinancing of its credit arrangements.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-06-17
Item 7.01
QVC Inc. and its affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas on April 16, 2026. Although this Item 7.01 disclosure focuses on the filing of monthly operating reports required by the Bankruptcy Code, it explicitly references and incorporates the prior 8-K filing disclosing the Chapter 11 Cases themselves. The bankruptcy filing is the material event that triggered this disclosure and is terminal in nature, representing the most significant financial distress signal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
This 8-K discloses the results of Annovis Bio's 2026 Annual Meeting of Stockholders held on June 17, 2026, under Item 5.07. The filing reports voting outcomes for five proposals: election of five directors, ratification of Ernst & Young LLP as independent auditors, amendment to the 2019 Equity Incentive Plan to increase authorized shares, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. All proposals were approved. This is a routine but material shareholder vote disclosure required by Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
Dogwood Therapeutics held its Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on five proposals: election of seven directors, ratification of Forvis Mazars, LLP as auditor, amendment to the Certificate of Incorporation to increase authorized shares, Say-on-Frequency advisory vote, and Say-on-Pay advisory vote. All proposals were approved by the required vote margins.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-17
Item 5.07
This 8-K Item 5.07 discloses the results of MaxCyte's 2026 annual stockholder meeting held on June 17, 2026, including voting outcomes for two proposals: election of three Class II directors (Patrick Balthrop, Cynthia Collins, and Stanley Erck) and ratification of CohnReznick LLP as the independent auditor. The tabulated vote counts for each nominee and proposal are the core disclosure, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 7.01
The disclosure reports material regulatory clearances for the proposed merger between Paramount Skydance Corporation and Warner Bros. Discovery, Inc., including unconditional approval from Chinese antitrust authorities (June 17, 2026), DOJ clearance (June 12, 2026), and Spanish foreign direct investment approval (June 11, 2026). These are significant milestones in a major M&A transaction that would result in WBD becoming a wholly owned subsidiary of PSKY, directly affecting the registrant's control and structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-17
Item 5.02
The filing discloses the Board's approval and election of Gary D. Hicok to the Board of Directors effective July 1, 2026, and his appointment to the Technology Committee. This is a clear executive appointment event. While the disclosure also mentions standard non-employee director compensation (stock units and cash retainer), the principal action is the appointment itself, not a compensatory arrangement modification. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-17
Item 4.01
The filing discloses the dismissal of KPMG LLP as the Company's independent registered public accounting firm effective June 11, 2026, and the engagement of BDO USA, P.C. as the new auditor for fiscal year 2026. This is a classic auditor change event under Item 4.01. The disclosure confirms no disagreements or reportable events with the prior auditor, and no prior consultations with the new auditor on accounting matters, indicating a routine competitive selection process rather than a dispute-driven change.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Southern Copper priced a $1.25 billion senior unsecured notes offering at 5.350% due 2036. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financing activities, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or other defined event type). The disclosure of a substantial debt offering under Item 8.01 warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-17
Item 5.02
Cory T. Newsom was appointed as Chief Executive Officer effective upon the retirement of Curtis C. Griffith on December 31, 2026. Newsom, an internal candidate with deep institutional knowledge as President since 2019 and board member since 2008, will assume leadership while Griffith remains as Chairman.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.02
South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-17
Item 1.01
Bed Bath & Beyond entered into a Merger Agreement and Plan of Reorganization with Fathom Holdings Inc. on June 16, 2026, whereby Fathom will merge with a wholly owned subsidiary of the Company, with Fathom surviving as a subsidiary of Bed Bath & Beyond. This is a material acquisition involving an exchange ratio of 0.2236 shares of Company Common Stock per FTHM share, subject to customary closing conditions and stockholder approval. The transaction is clearly a material change of control requiring Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-17
Item 8.01
The filing discloses a merger transaction between Sila Realty Trust and Sunshine Ultimate Parent LLC, with a special stockholder meeting scheduled for June 26, 2026 to approve the merger. The Item 8.01 disclosure supplements the proxy statement with updated financial advisor analyses and background information regarding the merger process, including contact with 81 potential buyers. This is a material acquisition/change of control event that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →